Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 29, 2026 02:54 ET | Source: Hopstem Biotechnology Inc.

Hopstem Receives U.S. FDA IND Clearance and Fast Track designations for hNPC01 in Hemorrhagic Stroke and Traumatic Brain Injury-Expanding Clinical Development Across Three Major Brain Injury Indications

HOUSTON, July 29, 2026 (GLOBE NEWSWIRE) -- Hopstem Biotechnology announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application and Fast Track...
June 03, 2026 05:40 ET | Source: Hopstem Biotechnology Inc.

Hopstem hNPC01 Cell Injection Earns FDA RMAT Designation for Chronic Stroke Therapy

HOUSTON, June 03, 2026 (GLOBE NEWSWIRE) -- Hopstem Biotechnology, a clinical-stage biotech specializing in iPSC-derived cell therapeutics for neurological diseases, has secured the first...
January 21, 2026 02:46 ET | Source: Hopstem Biotechnology Inc.

FDA Granted Hopstem’s hNPC01 for Chronic Ischemic Stroke Approval to Enter Phase 2/3 Adaptive Pivotal Clinical Trial with Bridging Study

FDA Granted Hopstem’s hNPC01 for Chronic Ischemic Stroke Approval to Enter Phase 2/3 Adaptive Pivotal Clinical Trial with Bridging Study